Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).

Journal of medicinal chemistry - 26 Sept 2013

Liu Wei, Yu Bing, Xu Gang, Xu Wei-Ren, Loh Mignon L, Tang Li-Da, Qu Cheng-Kui

Abstract excerpt

Activating mutations of PTPN11 (encoding the SHP2 phosphatase) are associated with Noonan syndrome, childhood leukemias, and sporadic solid tumors. Virtual screening combined with experimental assays was performed to identify inhibitors of SHP2 from a database of natural products. This effort led to the identification of cryptotanshinone as an inhibitor of SHP2. Cryptotanshinone inhibited SHP2 with an IC50 of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalytic Domain
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Evaluation, Preclinical

Share to Enzyme Activation

Share to Enzyme Inhibitors

Share to Models, Molecular

Share to Phenanthrenes

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Source

Open in PubMed Open full text

Identifiers

PMID: 23957426
DOI: 10.1021/jm400474r
PMCID: PMC4159095

Genes

PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).PMID 23957426Read ↗

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.Semantic proximity Read ↗

Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).Semantic proximity Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

SFX-01 is therapeutic against myeloproliferative disorders caused by activating mutations in Shp2.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.Semantic proximity Read ↗

Shp2, a novel oncogenic tyrosine phosphatase and potential therapeutic target for human leukemia.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein InteractionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.